stockrowRhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
Follow RYTM
Alert me
Rhythm Pharmaceuticals, Inc. (RYTM) EV/Sales
As of 5 November 2026, Rhythm Pharmaceuticals, Inc. (RYTM) trades at a EV/Sales of 24.3×. Over the past ten years it has ranged from −18.2× (May 2022) to 99.0× (March 2022); the current reading is higher than 61% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 34.6× | 45.55% |
| FY2024 | 23.8× | (20.88%) |
| FY2023 | 30.1× | (38.73%) |
| FY2022 | 49.1× | (22.71%) |
| FY2021 | 63.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 22.3× | (26.64%) |
| Jun 2026 | 30.4× | 18.36% |
| Mar 2026 | 25.7× | (25.87%) |
| Dec 2025 | 34.6× | (3.86%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.0× |
| CORT Corcept Therapeutics Incorporated compare | 7.6× |
| AXSM Axsome Therapeutics, Inc. compare | 7.6× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 11.2× |
| RYTM Rhythm Pharmaceuticals, Inc. | 24.3× |
| CYTK Cytokinetics, Incorporated compare | 65.9× |
| PRAX Praxis Precision Medicines, Inc. compare | 812× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on RYTM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement